Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP-700 dose-regimen study for colonoscopy sedation
NL-OMON29390Phase 2Suspended
- Sponsor
- The Medicines Company
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of moxetomidate in None (3 arms), sponsored by The Medicines Company. Primary endpoint: Successful completion of colonoscopy. Started Apr 2016; status: suspended.
02
Drugs
moxetomidate
Beyond the preview
Go deeper on NL-OMON29390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29390.